Advertisement

Topics

These highlights do not include all the information needed to use Pemetrexed for Injection safely and effectively. See full prescribing information for Pemetrexed for Injection. PEMETREXED for injection, for Intravenous Use Initial U.S. Approval: 2004 | Pemetrexed [Qilu Pharmaceutical Co., Ltd.] | BioPortfolio

12:38 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Pemetrexed for Injection is indicated in combination with cisplatin therapy for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer.

Pemetrexed for Injection is indicated for the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

Pemetrexed for Injection is indicated as a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy.

Pemetrexed for Injection in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

Pemetrexed for Injection is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. [see Clinical Studies (14.1, 14.2, 14.3)]

The recommended dose of Pemetrexed for Injection is 500 mg/m administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m infused over 2 hours beginning approximately 30 minutes after the end of Pemetrexed for Injection administration. See cisplatin package insert for more information.

The recommended dose of Pemetrexed for Injection is 500 mg/m administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.

Vitamin Supplementation

Instruct patients to initiate folic acid 400 mcg to 1000 mcg orally once daily beginning 7 days before the first dose of Pemetrexed for Injection. Continue folic acid during the full course of therapy and for 21 days after the last dose of Pemetrexed for Injection [see Warnings and Precautions (5.1)].

Administer vitamin B 1 mg intramuscularly 1 week prior to the first dose of Pemetrexed for Injection and every 3 cycles thereafter. Subsequent vitamin B injections may be given the same day as treatment with Pemetrexed for Injection [see Warnings and Precautions (5.1)].

Corticosteroids

Administer dexamethasone 4 mg by mouth twice daily the day before, the day of, and the day after Pemetrexed for Injection administration [see Warnings and Precautions (5.1)].

Monitoring

Complete blood cell counts, including platelet counts, should be performed on all patients receiving Pemetrexed for Injection. Patients should be monitored for nadir and recovery, which were tested in the clinical study before each dose and on days 8 and 15 of each cycle. Patients should not begin a new cycle of treatment unless the ANC is ≥1500 cells/mm, the platelet count is ≥100,000 cells/mm, and creatinine clearance is ≥45 mL/min. Periodic chemistry tests should be performed to evaluate renal and hepatic function [see Warnings and Precautions (5.5)].

Dose Reduction Recommendations

Dose adjustments at the start of a subsequent cycle should be based on nadir hematologic counts or maximum nonhematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery, patients should be retreated using the guidelines in Tables 1-3, which are suitable for using Pemetrexed for Injection as a single-agent or in combination with cisplatin.

If patients develop nonhematologic toxicities (excluding neurotoxicity) ≥Grade 3, treatment should be withheld until resolution to less than or equal to the patient's pre-therapy value. Treatment should be resumed according to guidelines in Table 2.

In the event of neurotoxicity, the recommended dose adjustments for Pemetrexed for Injection and cisplatin are described in Table 3. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is experienced.

Table 1: Dose Reduction for Pemetrexed for Injection (single-agent or in combination) and Cisplatin – Hematologic Toxicities
a These criteria meet the CTC version 2.0 (NCI 1998) definition of ≥CTC Grade 2 bleeding.
Nadir ANC <500/mm3 and nadir platelets ≥50,000/mm3. 75% of previous dose (pemetrexed and cisplatin).
Nadir platelets <50,000/mm3 without bleeding regardless of nadir ANC. 75% of previous dose (pemetrexed and cisplatin).
Nadir platelets <50,000/mm3 with bleedinga, regardless of nadir ANC. 50% of previous dose (pemetrexed and cisplatin).
Table 2: Dose Reduction for Pemetrexed for Injection (single-agent or in combination) and Cisplatin – Nonhematologic Toxicitiesa , b
a NCI Common Toxicity Criteria (CTC).
b Excluding neurotoxicity (see Table 3).
Dose of Pemetrexed for Injection
(mg/m2)
Dose of Cisplatin
(mg/m2)
Any Grade 3 or 4 toxicities except mucositis 75% of previous dose 75% of previous dose
Any diarrhea requiring hospitalization (irrespective of Grade) or Grade 3 or 4 diarrhea 75% of previous dose 75% of previous dose
Grade 3 or 4 mucositis 50% of previous dose 100% of previous dose
Table 3: Dose Reduction for Pemetrexed for Injection (single-agent or in combination) and Cisplatin – Neurotoxicity
Dose of Pemetrexed for Injection Dose of Cisplatin
CTC Grade (mg/m2) (mg/m2)
0-1 100% of previous dose 100% of previous dose
2 100% of previous dose 50% of previous dose

Discontinuation Recommendation

Pemetrexed for Injection therapy should be discontinued if a patient experiences any hematologic or nonhematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.

Renally Impaired Patients

In clinical studies, patients with creatinine clearance ≥45 mL/min required no dose adjustments other than those recommended for all patients. Insufficient numbers of patients with creatinine clearance below 45 mL/min have been treated to make dosage recommendations for this group of patients [see Clinical Pharmacology (12.3)]. Therefore, Pemetrexed for Injection should not be administered to patients whose creatinine clearance is <45 mL/min using the standard Cockcroft and Gault formula (below) or GFR measured by Tc99m-DTPA serum clearance method:

Caution should be exercised when administering Pemetrexed for Injection concurrently with NSAIDs to patients whose creatinine clearance is <80 mL/min [see Drug Interactions (7.1)].

Males: [140 - Age in years] × Actual Body Weight (kg) = mL/min
72 × Serum Creatinine (mg/dL)
Females: Estimated creatinine clearance for males × 0.85

As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions of Pemetrexed for Injection. The use of gloves is recommended. If a solution of Pemetrexed for Injection contacts the skin, wash the skin immediately and thoroughly with soap and water. If Pemetrexed for Injection contacts the mucous membranes, flush thoroughly with water. Several published guidelines for handling and disposal of anticancer agents are available [see References (15)].

Pemetrexed for Injection is not a vesicant. There is no specific antidote for extravasation of Pemetrexed for Injection. To date, there have been few reported cases of Pemetrexed for Injection extravasation, which were not assessed as serious by the investigator. Pemetrexed for Injection extravasation should be managed with local standard practice for extravasation as with other non-vesicants.

Reconstitution and further dilution prior to intravenous infusion is only recommended with 0.9% Sodium Chloride Injection (preservative free). Pemetrexed for Injection is physically incompatible with diluents containing calcium, including Lactated Ringer's Injection, USP and Ringer's Injection, USP and therefore these should not be used. Coadministration of Pemetrexed for Injection with other drugs and diluents has not been studied, and therefore is not recommended. Pemetrexed for Injection is compatible with standard polyvinyl chloride (PVC) administration sets and intravenous solution bags.

Pemetrexed for Injection, is a white to either light-yellow or green-yellow lyophilized powder available in sterile single-use vials containing 100 mg or 500 mg pemetrexed.

Pemetrexed for Injection is contraindicated in patients who have a history of severe hypersensitivity reaction to pemetrexed.

Vitamin Supplementation

Prior to treatment with Pemetrexed for Injection, initiate supplementation with oral folic acid and intramuscular vitamin B to reduce the severity of hematologic and gastrointestinal toxicity of Pemetrexed for Injection [see Dosage and Administration (2.3)]. Do not substitute oral vitamin B for intramuscular vitamin B. In clinical studies, the incidence of the following Grade 3-4 toxicities were higher in patients with mesothelioma who were never supplemented as compared to patients who were fully supplemented with folic acid and vitamin B prior to and throughout Pemetrexed for Injection treatment: neutropenia [38% versus 23%], thrombocytopenia [9% versus 5%], febrile neutropenia [9% versus 0.6%], and infection with neutropenia [6% versus. 0].

Corticosteroids

Administer dexamethasone the day before, the day of, and the day after Pemetrexed for Injection administration [see Dosage and Administration (2.3)].

Pemetrexed for Injection can suppress bone marrow function, as manifested by neutropenia, thrombocytopenia, and anemia (or pancytopenia) [see Adverse Reactions (6.1)]; myelosuppression is usually the dose-limiting toxicity. Dose reductions for subsequent cycles are based on nadir ANC, platelet count, and maximum nonhematologic toxicity seen in the previous cycle [see Dosage and Administration (2.4)].

Pemetrexed for Injection is primarily eliminated unchanged by renal excretion. No dosage adjustment is needed in patients with creatinine clearance ≥45 mL/min. Insufficient numbers of patients have been studied with creatinine clearance <45 mL/min to give a dose recommendation. Therefore, Pemetrexed for Injection should not be administered to patients whose creatinine clearance is <45 mL/min [see Dosage and Administration (2.4)].

One patient with severe renal impairment (creatinine clearance 19 mL/min) who did not receive folic acid and vitamin B died of drug-related toxicity following administration of Pemetrexed for Injection alone.

Caution should be used when administering NSAIDs concurrently with Pemetrexed for Injection to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) [see Drug Interactions (7.1)].

Obtain a complete blood count and renal function tests at the beginning of each cycle and as needed. Do not initiate a cycle of treatment unless the ANC is ≥1500 cells/mm, the platelet count is ≥100,000 cells/mm, and creatinine clearance is ≥45 mL/min [see Dosage and Administration (2.4)].

Based on its mechanism of action, Pemetrexed for Injection can cause fetal harm when administered to a pregnant woman. Pemetrexed administered intraperitoneally to mice during organogenesis was embryotoxic, fetotoxic and teratogenic in mice at greater than 1/833rd the recommended human dose. If Pemetrexed for Injection is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Women should be advised to use effective contraceptive measures to prevent pregnancy during treatment with Pemetrexed for Injection [see Use in Specific Populations (8.1)].

Because clinical trials are conducted under widely varying conditions, adverse reactions rates cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.

In clinical trials, the most common adverse reactions (incidence ≥20%) during therapy with Pemetrexed for Injection as a single-agent were fatigue, nausea, and anorexia. Additional common adverse reactions (incidence ≥20%) during therapy with Pemetrexed for Injection when used in combination with cisplatin included vomiting, neutropenia, leukopenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation.

Non-Small Cell Lung Cancer (NSCLC) – Pemetrexed for Injection in Combination with Cisplatin

Table 4 provides the frequency and severity of adverse reactions that have been reported in >5% of 839 patients with NSCLC who were randomized to study and received Pemetrexed for Injection plus cisplatin and 830 patients with NSCLC who were randomized to study and received gemcitabine plus cisplatin. All patients received study therapy as initial treatment for locally advanced or metastatic NSCLC and patients in both treatment groups were fully supplemented with folic acid and vitamin B.

No clinically relevant differences in adverse reactions were seen in patients based on histology.

In addition to the lower incidence of hematologic toxicity on the Pemetrexed for Injection and cisplatin arm, use of transfusions (RBC and platelet) and hematopoietic growth factors was lower in the Pemetrexed for Injection and cisplatin arm compared to the gemcitabine and cisplatin arm.

The following additional adverse reactions were observed in patients with non-small cell lung cancer randomly assigned to receive Pemetrexed for Injection plus cisplatin.

Incidence 1% to 5%

Body as a Whole — febrile neutropenia, infection, pyrexia

General Disorders — dehydration

Metabolism and Nutrition — increased AST, increased ALT

Renal — creatinine clearance decrease, renal failure

Special Senses — conjunctivitis

Incidence Less than 1%

Cardiovascular — arrhythmia

General Disorders — chest pain

Metabolism and Nutrition — increased GGT

Neurology — motor neuropathy

Table 4: Adverse Reactions in Fully Supplemented Patients Receiving Pemetrexed for Injection plus Cisplatin in NSCLCa
a For the purpose of this table a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to Pemetrexed for Injection.
b Refer to NCI CTC Criteria version 2.0 for each Grade of toxicity.
c According to NCI CTC Criteria version 2.0, this adverse event term should only be reported as Grade 1 or 2.
Reactionb Pemetrexed for Injection/cisplatin
(N=839)
Gemcitabine/cisplatin
(N=830)
All Grades
Toxicity (%)
Grade 3-4
Toxicity (%)
All Grades
Toxicity (%)
Grade 3-4
Toxicity (%)
All Adverse Reactions 90 37 91 53
 Laboratory
  Hematologic
   Anemia 33 6 46 10
   Neutropenia 29 15 38 27
   Leukopenia 18 5 21 8
   Thrombocytopenia 10 4 27 13
  Renal
   Creatinine elevation 10 1 7 1
 Clinical
  Constitutional Symptoms
   Fatigue 43 7 45 5
  Gastrointestinal
   Nausea 56 7 53 4
   Vomiting 40 6 36 6
   Anorexia 27 2 24 1
   Constipation 21 1 20 0
   Stomatitis/Pharyngitis 14 1 12 0
   Diarrhea 12 1 13 2
   Dyspepsia/Heartburn 5 0 6 0
  Neurology
   Neuropathy-sensory 9 0 12 1
   Taste disturbance 8 0c 9 0c
  Dermatology/Skin
   Alopecia 12 0c 21 1c
   Rash/Desquamation 7 0 8 1

Non-Small Cell Lung Cancer (NSCLC) – Maintenance

Pemetrexed for Injection Maintenance Following Non-Pemetrexed for Injection Containing, Platinum-Based Induction Therapy

Table 5 provides the frequency and severity of adverse reactions reported in >5% of the 438 patients with NSCLC who received Pemetrexed for Injection maintenance and the 218 patients with NSCLC who received placebo following a platinum-based induction therapy.

All patients received study therapy immediately following 4 cycles of platinum-based treatment for locally advanced or metastatic NSCLC. Patients in both study arms were fully supplemented with folic acid and vitamin B.

No clinically relevant differences in Grade 3/4 adverse reactions were seen in patients based on age, gender, ethnic origin, or histology except a higher incidence of Grade 3/4 fatigue for Caucasian patients compared to non-Caucasian patients (6.5% versus 0.6%).

Safety was assessed by exposure for patients who received at least one dose of Pemetrexed for Injection (N=438). The incidence of adverse reactions was evaluated for patients who received ≤6 cycles of Pemetrexed for Injection, and compared to patients who received >6 cycles of Pemetrexed for Injection. Increases in adverse reactions (all grades) were observed with longer exposure; however no clinically relevant differences in Grade 3/4 adverse reactions were seen.

Consistent with the higher incidence of anemia (all grades) on the Pemetrexed for Injection arm, use of transfusions (mainly RBC) and erythropoiesis stimulating agents (ESAs; erythropoietin and darbepoetin) were higher in the Pemetrexed for Injection arm compared to the placebo arm (transfusions 9.5% versus 3.2%, ESAs 5.9% versus 1.8%).

The following additional adverse reactions were observed in patients with non-small cell lung cancer who received Pemetrexed for Injection.

Incidence 1% to 5%

Dermatology/Skin — alopecia, pruritis/itching

Gastrointestinal — constipation

General Disorders — edema, fever (in the absence of neutropenia)

Hematologic — thrombocytopenia

Renal — decreased creatinine clearance, increased creatinine, decreased glomerular filtration rate

Special Senses — ocular surface disease (including conjunctivitis), increased lacrimation

Incidence Less than 1%

Cardiovascular — supraventricular arrhythmia

Dermatology/Skin — erythema multiforme

General Disorders — febrile neutropenia, allergic reaction/hypersensitivity

Neurology — motor neuropathy

Renal — renal failure

Table 5: Adverse Reactions in Patients Receiving Pemetrexed for Injection versus Placebo in NSCLCa Following Platinum-Based Induction Therapy
a For the purpose of this table a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to Pemetrexed for Injection.
b Refer to NCI CTCAE Criteria version 3.0 for each Grade of toxicity.
Pemetrexed for Injection
(N=438)
Placebo
(N=218)
Reactionb All Grades
Toxicity (%)
Grade 3-4
Toxicity (%)
All Grades
Toxicity (%)
Grade 3-4
Toxicity (%)
All Adverse Reactions 66 16 37 4
 Laboratory
  Hematologic
  Anemia 15 3 6 1
  Neutropenia 6 3 0 0
  Leukopenia 6 2 1 1
 Hepatic
  Increased ALT 10 0 4 0
  Increased AST 8 0 4 0
 Clinical
 Constitutional Symptoms
  Fatigue 25 5 11 1
 Gastrointestinal
  Nausea 19 1 6 1
  Anorexia 19 2 5 0
  Vomiting 9 0 1 0
  Mucositis/stomatitis 7 1 2 0
  Diarrhea 5 1 3 0
 Infection 5 2 2 0
 Neurology
  Neuropathy-sensory 9 1 4 0
 Dermatology/Skin
  Rash/Desquamation 10 0 3 0

Continuation of Pemetrexed for Injection as Maintenance Following Pemetrexed for Injection Plus Platinum Induction Therapy

Table 6 provides the frequency and severity of adverse reactions reported in >5% of the 500 patients with non-squamous NSCLC who received at least one cycle of Pemetrexed for Injection maintenance (n=333) or placebo (n=167) on the continuation maintenance trial.

The median of maintenance cycles administered to patients receiving one or more doses of maintenance therapy was 4 on both the pemetrexed and placebo arms. Dose reductions for adverse events occurred in 3.3% of patients in the Pemetrexed for Injection arm and 0.6% in the placebo arm. Dose delays for adverse events occurred in 22% of patients in the Pemetrexed for Injection arm and 16% in the placebo arm. Patients in both study arms were supplemented with folic acid and vitamin B.

Administration of RBC (13% versus 4.8%) and platelet (1.5% versus 0.6%) transfusions, erythropoiesis stimulating agents (12% versus 7%), and granulocyte colony stimulating factors (6% versus 0) were higher in the Pemetrexed for Injection arm compared to the placebo arm.

The following additional Grade 3 or 4 adverse reactions were observed more frequently in the Pemetrexed for Injection arm.

Incidence 1% to 5%

Blood/Bone Marrow — thrombocytopenia

General Disorders — febrile neutropenia

Incidence Less than 1%

Cardiovascular — ventricular tachycardia, syncope

General Disorders — pain

Gastrointestinal — gastrointestinal obstruction

Neurologic — depression

Renal — renal failure

Vascular — pulmonary embolism

Table 6: Selecteda Adverse Reactionsb Occurring in ≥5% of Patients Receiving Pemetrexed for Injection in Nonsquamous NSCLC Following Pemetrexed for Injection Plus Cisplatin Induction Therapy
a Adverse reactions of any severity (all grades) occurring more frequently (≥5%) or Grade 3-4 adverse reactions occurring more frequently (≥2%) in Pemetrexed for Injection-treated patients compared to those receiving placebo.
b NCI CTCAE Criteria version 3.0
Adverse Reaction Organ System and Term Pemetrexed for Injection
(N=333)
Placebo
(N=167)
All Gradesa
Toxicity (%)
Grade 3-4a
Toxicity (%)
All Gradesa
Toxicity (%)
Grades 3-4a
Toxicity (%)
All Adverse Reactions 53 17 34 4.8
Laboratory
Hematologic
   Anemia 15 4.8 4.8 0.6
   Neutropenia 9 3.9 0.6 0
Clinical
Constitutional Symptoms
   Fatigue 18 4.5 11 0.6
Gastrointestinal
   Nausea 12 0.3 2.4 0
   Vomiting 6 0 1.8 0
   Mucositis/stomatitis 5 0.3 2.4 0
General Disorders
   Edema 5 0 3.6 0

Non-Small Cell Lung Cancer (NSCLC) – After Prior Chemotherapy

Table 7 provides the frequency and severity of adverse reactions that have been reported in >5% of 265 patients randomly assigned to receive single-agent Pemetrexed for Injection with folic acid and vitamin B supplementation and 276 patients randomly assigned to receive single-agent docetaxel. All patients were diagnosed with locally advanced or metastatic NSCLC and received prior chemotherapy.

No clinically relevant differences in adverse reactions were seen in patients based on histology.

Clinically relevant adverse reactions occurring in <5% of patients that received Pemetrexed for Injectiontreatment but >5% of patients that received docetaxel include CTC Grade 3/4 febrile neutropenia (1.9% Pemetrexed for Injection, 12.7% docetaxel).

The following additional adverse reactions were observed in patients with non-small cell lung cancer randomly assigned to receive Pemetrexed for Injection.

Incidence 1% to 5%

Body as a Whole — abdominal pain, allergic reaction/hypersensitivity, febrile neutropenia, infection

Dermatology/Skin — erythema multiforme

Neurology — motor neuropathy, sensory neuropathy

Renal — increased creatinine

Incidence Less than 1%

Cardiovascular — supraventricular arrhythmias

Table 7: Adverse Reactions in Fully Supplemented Patients Receiving Pemetrexed for Injection versus Docetaxel in NSCLCa
a For the purpose of this table a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to Pemetrexed for Injection.
b Refer to NCI CTC Criteria for lab values for each Grade of toxicity (version 2.0).
c According to NCI CTC Criteria version 2.0, this adverse event term should only be reported as Grade 1 or 2.
Pemetrexed for Injection
(N=265)
Docetaxel
(N=276)
Reactionb All Grades
Toxicity (%)
Grades 3-4
Toxicity (%)
All Grades
Toxicity (%)
Grades 3-4
Toxicity (%)
 Laboratory
  Hematologic
   Anemia 19 4 22 4
   Leukopenia 12 4 34 27
   Neutropenia 11 5 45 40
   Thrombocytopenia 8 2 1 0
  Hepatic
   Increased ALT 8 2 1 0
   Increased AST 7 1 1 0
 Clinical
  Gastrointestinal
   Nausea 31 3 17 2
   Anorexia 22 2 24 3
   Vomiting 16 2 12 1
   Stomatitis/Pharyngitis 15 1 17 1
   Diarrhea 13 0 24 3
   Constipation 6 0 4 0
  Constitutional Symptoms
   Fatigue 34 5 36 5
   Fever 8 0 8 0
  Dermatology/Skin
   Rash/Desquamation 14 0 6 0
   Pruritis 7 0 2 0
   Alopecia 6 1c 38 2c

Malignant Pleural Mesothelioma (MPM)

Table 8 provides the frequency and severity of adverse reactions that have been reported in >5% of 168 patients with mesothelioma who were randomly assigned to receive cisplatin and Pemetrexed for Injection and 163 patients with mesothelioma randomly assigned to receive single-agent cisplatin. In both treatment arms, these chemonaive patients were fully supplemented with folic acid and vitamin B.

The following additional adverse reactions were observed in patients with malignant pleural mesothelioma randomly assigned to receive Pemetrexed for Injection plus cisplatin.

Incidence 1% to 5%

Body as a Whole — febrile neutropenia, infection, pyrexia

Dermatology/Skin — urticaria

General Disorders — chest pain

Metabolism and Nutrition — increased AST, increased ALT, increased GGT

Renal — renal failure

Incidence Less than 1%

Cardiovascular — arrhythmia

Neurology — motor neuropathy

Table 8: Adverse Reactions in Fully Supplemented Patients Receiving Pemetrexed for Injection plus Cisplatin in MPMa
a For the purpose of this table a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to Pemetrexed for Injection.
b Refer to NCI CTC Criteria version 2.0 for each Grade of toxicity except the term “creatinine clearance decreased” which is derived from the CTC term “renal/genitourinary-other”.
c According to NCI CTC Criteria version 2.0, this adverse event term should only be reported as Grade 1 or 2.
Pemetrexed for Injection/cisplatin
(N=168)
Cisplatin
(N=163)
Reactionb All Grades Toxicity (%) Grade 3-4 Toxicity (%) All Grades Toxicity (%) Grade 3-4 Toxicity (%)
 Laboratory
  Hematologic
   Neutropenia 56 23 13 3
   Leukopenia 53 15 17 1
   Anemia 26 4 10 0
   Thrombocytopenia 23 5 9 0
  Renal
   Creatinine elevation 11 1 10 1
   Creatinine clearance decreased 16 1 18 2
 Clinical
  Eye Disorder
   Conjunctivitis 5 0 1 0
  Gastrointestinal
   Nausea 82 12 77 6
   Vomiting 57 11 50 4
   Stomatitis/Pharyngitis 23 3 6 0
   Anorexia 20 1 14 1
   Diarrhea 17 4 8 0
   Constipation 12 1 7 1
   Dyspepsia 5 1 1 0
  Constitutional Symptoms
   Fatigue 48 10 42 9
  Metabolism and Nutrition
   Dehydration 7 4 1 1
  Neurology
   Neuropathy-sensory 10 0 10 1
   Taste Disturbance 8 0c 6 0c
  Dermatology/Skin
   Rash 16 1 5 0
   Alopecia 11 0c 6 0c

Effects of Vitamin Supplementations on Toxicity

Table 9 compares the incidence (percentage of patients) of CTC Grade 3/4 toxicities in patients who received vitamin supplementation with daily folic acid and vitamin B from the time of enrollment in the study (fully supplemented) with the incidence in patients who never received vitamin supplementation (never supplemented) during the study in the Pemetrexed for Injection plus cisplatin arm.

The following adverse events were greater in the fully supplemented group compared to the never supplemented group: hypertension (11%, 3%), chest pain (8%, 6%), and thrombosis/embolism (6%, 3%).

No relevant effect for Pemetrexed for Injection safety due to gender or race was identified, except an increased incidence of rash in men (24%) compared to women (16%).

Table 9: Selected Grade 3/4 Adverse Events Comparing Fully Supplemented versus Never Supplemented Patients in the Pemetrexed for Injection plus Cisplatin arm (% incidence)
a Refer to NCI CTC criteria for lab and non-laboratory values for each grade of toxicity (Version 2.0).
Adverse Eventa (%) Fully Supplemented Patients
(N=168)
Never Supplemented Patients
(N=32)
Neutropenia/granulocytopenia 23 38
Thrombocytopenia 5 9
Vomiting 11 31
Febrile neutropenia 1 9
Infection with Grade 3/4 neutropenia 0 6
Diarrhea 4 9

Additional Experience Across Clinical Trials

Sepsis, which in some cases was fatal, occurred in approximately 1% of patients.

Esophagitis occurred in less than 1% of patients.

The following adverse reactions have been identified during post-approval use of Pemetrexed for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These reactions occurred with Pemetrexed for Injection when used as a single-agent and in combination therapies.

Blood and Lymphatic System — immune-mediated hemolytic anemia

Gastrointestinal — colitis, pancreatitis

General Disorders and Administration Site Conditions — edema

Injury, poisoning, and procedural complications — Radiation recall has been reported in patients who have previously received radiotherapy.

Respiratory — interstitial pneumonitis

Skin — Bullous conditions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Some cases were fatal.

Although ibuprofen (400 mg four times a day) can decrease the clearance of pemetrexed, it can be administered with Pemetrexed for Injection in patients with normal renal function (creatinine clearance ≥80 mL/min). No dose adjustment of Pemetrexed for Injection is needed with concomitant NSAIDs in patients with normal renal function [see Clinical Pharmacology (12.3)].

Caution should be used when administering NSAIDs concurrently with Pemetrexed for Injection to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of 2 days before, the day of, and 2 days following administration of Pemetrexed for Injection.

In the absence of data regarding potential interaction between Pemetrexed for Injection and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following Pemetrexed for Injection administration. If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression, renal, and gastrointestinal toxicity.

Pemetrexed for Injection is primarily eliminated unchanged renally as a result of glomerular filtration and tubular secretion. Concomitant administration of nephrotoxic drugs could result in delayed clearance of Pemetrexed for Injection. Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of Pemetrexed for Injection.

Teratogenic Effects – Pregnancy Category D [see Warnings and Precautions (5.6)]

Based on its mechanism of action, Pemetrexed for Injection can cause fetal harm when administered to a pregnant woman. There are no adequate and well controlled studies of Pemetrexed for Injection in pregnant women. Pemetrexed was embryotoxic, fetotoxic, and teratogenic in mice. In mice, repeated intraperitoneal doses of pemetrexed when given during organogenesis caused fetal malformations (incomplete ossification of talus and skull bone; about 1/833rd the recommended intravenous human dose on a mg/m basis), and cleft palate (1/33rd the recommended intravenous human dose on a mg/m basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced litter sizes. If Pemetrexed for Injection is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to use effective contraceptive measures to prevent pregnancy during the treatment with Pemetrexed for Injection.

It is not known whether Pemetrexed for Injection or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Pemetrexed for Injection, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug for the mother.

Efficacy of Pemetrexed for Injection in pediatric patients has not been demonstrated. Pemetrexed for Injection was administered as an intravenous infusion over 10 minutes on Day 1 of a 21 day cycle to pediatric patients with recurrent solid tumors in a Phase 1 study (32 patients) and a Phase 2 study (72 patients). All patients received pretreatment with vitamin B and folic acid supplementation and dexamethasone. The dose escalation in the Phase 1 study determined the maximum tolerated dose was 1910 mg/m and this dose (or 60 mg/kg for patients <12 months old) was evaluated in the Phase 2 study of patients with relapsed or refractory osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET, or non-brainstem high grade glioma. No responses were observed among the 72 patients in this Phase 2 trial. The most common toxicities reported were hematological (leukopenia, neutropenia/granulocytopenia, anemia, thrombocytopenia, and lymphopenia), liver function abnormalities (increased ALT/AST), fatigue, and nausea.

The single dose pharmacokinetics of Pemetrexed for Injection administered in doses ranging from 400 to 2480 mg/m were evaluated in the Phase 1 trial in 22 patients (13 males and 9 females) aged 4 to 18 years (average age 12 years). Pemetrexed exposure (AUC and C) appeared to increase proportionally with dose. The average pemetrexed clearance (2.30 L/h/m) and half-life (2.3 hours) in pediatric patients were comparable to values reported in adults.

Pemetrexed for Injection is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Renal function monitoring is recommended with administration of Pemetrexed for Injection. No dose reductions other than those recommended for all patients are necessary for patients 65 years of age or older [see Dosage and Administration (2.4)].

Of 3,946 patients (34.0% ≥65) studied across the five clinical trials [see Clinical Studies (14.1, 14.2, 14.3, and 14.4)], the effect of Pemetrexed for Injection on survival was similar in patients <65 compared to ≥65 years of age. There were no differences in safety with the exception of the following Grade 3-4 adverse reactions, which were noted in at least one of the five trials to be greater in patients 65 years of age and older as compared to younger patients: anemia, fatigue, thrombocytopenia, hypertension, and neutropenia.

There was no effect of elevated AST, ALT, or total bilirubin on the pharmacokinetics of pemetrexed. However, no formal studies have been conducted to examine the pharmacokinetics of pemetrexed in patients with hepatic impairment [see Clinical Pharmacology (12.3)].

Pemetrexed for Injection is known to be primarily excreted by the kidneys. Decreased renal function will result in reduced clearance and greater exposure (AUC) to Pemetrexed for Injection compared with patients with normal renal function [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. Cisplatin coadministration with Pemetrexed for Injection has not been studied in patients with moderate renal impairment.

Of 3,946 patients (Male 70.5%) studied across the five registration studies for Pemetrexed for Injection indications [see Clinical Studies (14.1, 14.2, 14.3, and 14.4)], the effect of Pemetrexed for Injection on survival was similar in female and male patients.

Of 3,946 patients (Caucasian 78.6%) studied across the five registration studies for Pemetrexed for Injection indications [see Clinical Studies (14.1, 14.2, 14.3, and 14.4)], the effect of Pemetrexed for Injection on survival was similar in the Caucasian and non-Caucasian patients.

There have been few cases of Pemetrexed for Injection overdose. Reported toxicities included neutropenia, anemia, thrombocytopenia, mucositis, and rash. Anticipated complications of overdose include bone marrow suppression as manifested by neutropenia, thrombocytopenia, and anemia. In addition, infection with or without fever, diarrhea, and mucositis may be seen. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician.

In clinical trials, leucovorin was permitted for CTC Grade 4 leukopenia lasting ≥3 days, CTC Grade 4 neutropenia lasting ≥3 days, and immediately for CTC Grade 4 thrombocytopenia, bleeding associated with Grade 3 thrombocytopenia, or Grade 3 or 4 mucositis. The following intravenous doses and schedules of leucovorin were recommended for intravenous use: 100 mg/m, intravenously once, followed by leucovorin, 50 mg/m, intravenously every 6 hours for 8 days.

The ability of Pemetrexed for Injection to be dialyzed is unknown.

Pemetrexed disodium hemipentahydrate has the chemical name L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, hemipentahydrate. It is a white to almost-white solid with a molecular formula of CHNNaO•2.5HO and a molecular weight of 516.41. The structural formula is as follows:

Pemetrexed for Injection is supplied as a sterile lyophilized powder for intravenous infusion available in single-dose vials. The product is a white to either light yellow or green-yellow lyophilized solid. Each 100-mg or 500-mg vial of Pemetrexed for Injection contains pemetrexed disodium equivalent to 100 mg pemetrexed and 106 mg mannitol or 500 mg pemetrexed and 500 mg mannitol, respectively. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH.

Pemetrexed for Injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.

Absolute neutrophil counts (ANC) following single-agent administration of Pemetrexed for Injection to patients not receiving folic acid and vitamin B supplementation were characterized using population pharmacodynamic analyses. Severity of hematologic toxicity, as measured by the depth of the ANC nadir, correlates with the systemic exposure, or area under the curve (AUC) of pemetrexed. It was also observed that lower ANC nadirs occurred in patients with elevated baseline cystathionine or homocysteine concentrations. The levels of these substances can be reduced by folic acid and vitamin B supplementation. There is no cumulative effect of pemetrexed exposure on ANC nadir over multiple treatment cycles.

Time to ANC nadir with pemetrexed systemic exposure (AUC), varied between 8 to 9.6 days over a range of exposures from 38.3 to 316.8 mcg•hr/mL. Return to baseline ANC occurred 4.2 to 7.5 days after the nadir over the same range of exposures.

Absorption

The pharmacokinetics of Pemetrexed for Injection administered as a single-agent in doses ranging from 0.2 to 838 mg/m infused over a 10-minute period have been evaluated in 426 cancer patients with a variety of solid tumors. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration (C) increase proportionally with dose. The pharmacokinetics of pemetrexed do not change over multiple treatment cycles.

Distribution

Pemetrexed has a steady-state volume of distribution of 16.1 liters. In vitro studies indicate that pemetrexed is approximately 81% bound to plasma proteins. Binding is not affected by degree of renal impairment.

Metabolism and Excretion

Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration. The clearance decreases, and exposure (AUC) increases, as renal function decreases. The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).

The pharmacokinetics of pemetrexed in special populations were examined in about 400 patients in controlled and single arm studies.

In vitro studies indicate that pemetrexed is a substrate of OAT3 (organic anion transporter 3), a transporter that may play a role in active secretion of pemetrexed.

Effect of Age, Gender or Race

No effect of age on the pharmacokinetics of pemetrexed was observed over a range of 26 to 80 years.

The pharmacokinetics of pemetrexed were not different in male and female patients.

The pharmacokinetics of pemetrexed were similar in Caucasians and patients of African descent. Insufficient data are available to compare pharmacokinetics for other ethnic groups.

Effect of Hepatic Insufficiency

There was no effect of elevated AST, ALT, or total bilirubin on the pharmacokinetics of pemetrexed. However, studies of hepatically impaired patients have not been conducted [see Dosage and Administration (2.4) and Use in Specific Populations (8.6)].

Effect of Renal Insufficiency

Pharmacokinetic analyses of pemetrexed included 127 patients with reduced renal function. Plasma clearance of pemetrexed decreases as renal function decreases, with a resultant increase in systemic exposure. Patients with creatinine clearances of 45, 50, and 80 mL/min had 65%, 54%, and 13% increases, respectively in pemetrexed total systemic exposure (AUC) compared to patients with creatinine clearance of 100 mL/min [see Warnings and Precautions (5.4) and Dosage and Administration (2.4)].

Effect of Third Space Fluid

The effect of third space fluid, such as pleural effusion and ascites, on Pemetrexed for Injection is not fully defined. A study of Pemetrexed for Injection 500 mg/m was performed in 31 solid tumor patients with stable third space fluid (All but 2 of the 31 patients included in study had mild or moderate amounts of third space fluid). Moderate pleural effusion was defined in the study as less than 1/3 the way up on one side with obscuring of the entire hemidiaphragm. Moderate ascites was defined as that detectable on physical exam. The pemetrexed plasma concentrations in these patients were comparable to those observed in previous clinical trials in patients without third space fluid collections. Thus, drainage of mild or moderate third space fluid collection prior to Pemetrexed for Injection treatment should be considered, but is probably not necessary. The effect of severe third space fluid on pharmacokinetics is not known.

Effect of Ibuprofen

Ibuprofen doses of 400 mg four times a day reduce pemetrexed's clearance by about 20% (and increase AUC by 20%) in patients with normal renal function. The effect of greater doses of ibuprofen on pemetrexed pharmacokinetics is unknown [see Drug Interactions (7.1)].

Effect of Aspirin

Aspirin, administered in low to moderate doses (325 mg every 6 hours), does not affect the pharmacokinetics of pemetrexed. The effect of greater doses of aspirin on pemetrexed pharmacokinetics is unknown.

Effect of Cisplatin

Cisplatin does not affect the pharmacokinetics of pemetrexed and the pharmacokinetics of total platinum are unaltered by pemetrexed.

Effect of Vitamins

Coadministration of oral folic acid or intramuscular vitamin B does not affect the pharmacokinetics of pemetrexed.

Drugs Metabolized by Cytochrome P450 Enzymes

Results from in vitro studies with human liver microsomes predict that pemetrexed would not cause clinically significant inhibition of metabolic clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.

No carcinogenicity studies have been conducted with pemetrexed. Pemetrexed was clastogenic in the in vivo micronucleus assay in mouse bone marrow but was not mutagenic in multiple in vitro tests (Ames assay, CHO cell assay). Pemetrexed administered at i.v. doses of 0.1 mg/kg/day or greater to male mice (about 1/1666 the recommended human dose on a mg/m basis) resulted in reduced fertility, hypospermia, and testicular atrophy.

A multi-center, randomized, open-label study in 1725 chemonaive patients with Stage IIIb/IV NSCLC was conducted to compare the overall survival following treatment with Pemetrexed for Injection in combination with cisplatin (PC) versus gemcitabine in combination with cisplatin (GC). Pemetrexed for Injection was administered intravenously over 10 minutes at a dose of 500 mg/m with cisplatin administered intravenously at a dose of 75 mg/m after Pemetrexed for Injection administration, on Day 1 of each 21-day cycle. Gemcitabine was administered at a dose of 1250 mg/m on Day 1 and Day 8, and cisplatin was administered intravenously at a dose of 75 mg/m after administration of gemcitabine, on Day 1 of each 21-day cycle. Treatment was administered up to a total of 6 cycles, and patients in both treatment arms received folic acid, vitamin B, and dexamethasone [see Dosage and Administration (2.3)].

Patient demographics of the intent to treat (ITT) population are shown in Table 10. The demographics and disease characteristics were well balanced.

Patients received a median of 5 cycles of treatment in both study arms. Patients treated with Pemetrexed for Injection plus cisplatin received a relative dose intensity of 94.8% of the protocol-specified Pemetrexed for Injection dose intensity and 95.0% of the protocol-specified cisplatin dose intensity. Patients treated with gemcitabine plus cisplatin received a relative dose intensity of 85.8% of the protocol-specified gemcitabine dose intensity and 93.5% of the protocol-specified cisplatin dose intensity.

The primary endpoint in this study was overall survival. The median survival time was 10.3 months in the Pemetrexed for Injection plus cisplatin treatment arm and 10.3 months in the gemcitabine plus cisplatin arm, with an adjusted hazard ratio of 0.94.

Figure 1: Kaplan-Meier Curves for Overall Survival Pemetrexed for Injection plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) in NSCLC – ITT Population.

A pre-specified analysis of the impact of NSCLC histology on overall survival was examined. Clinically relevant differences in survival according to histology were observed and are shown in Table 12. This difference in treatment effect for Pemetrexed for Injection based on histology demonstrating a lack of efficacy in squamous cell histology was also observed in the single-agent, second-line study and the maintenance study [see Clinical Studies (14.2, 14.3)].

Figure 2: Kaplan-Meier Curves for Overall Survival Pemetrexed for Injection plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) in NSCLC – Nonsquamous NSCLC and Squamous Cell NSCLC.

Table 10: First-Line Therapy: Summary of Patient Characteristics in Study of NSCLC
a Includes adenocarcinoma, large cell, and other histologies except those with squamous cell type.
b The subgroup of "other" represents patients with a primary diagnosis of NSCLC whose disease did not clearly qualify as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.
c Eastern Cooperative Oncology Group Performance Status.
d ECOG PS was not reported for all randomized patients. Percentages are representative of N=861 for the Pemetrexed for Injection plus cisplatin arm, and N=861 for the gemcitabine plus cisplatin arm.
e Smoking history was collected for 88% of randomized patients (N=757 for the Pemetrexed for Injection plus cisplatin arm and N=759 for the gemcitabine plus cisplatin arm).
Patient characteristic Pemetrexed for Injection plus Cisplatin (PC)
(N=862)
Gemcitabine plus Cisplatin (GC)
(N=863)
Age (yrs)
 Median (range) 61.1 (28.8-83.2) 61.0 (26.4-79.4)
Gender
 Male/Female 70.2%/29.8% 70.1%/29.9%
Origin
 Caucasian 669 (77.6%) 680 (78.8%)
 Hispanic 27 (3.1%) 23 (2.7%)
 Asian 146 (16.9%) 141 (16.3%)
 African descent 18 (2.1%) 18 (2.1%)
Stage at Entry
 IIIb/IV 23.8%/76.2% 24.3%/75.7%
Histology
 Nonsquamous NSCLCa 618 (71.7%) 634 (73.5%)
  Adenocarcinoma 436 (50.6%) 411 (47.6%)
  Large cell 76 (8.8%) 77 (8.9%)
  Otherb 106 (12.3%) 146 (16.9%)
 Squamous 244 (28.3%) 229 (26.5%)
ECOG PSc,d
 0/1 35.4%/64.6% 35.6%/64.3%
Smoking Historye
 Ever/never smoker 83.1%/16.9% 83.9%/16.1%
Table 11: First-Line Therapy: Efficacy in NSCLC – ITT Population
a Adjusted for gender, stage, basis of diagnosis, and performance status.
b A HR that is less than 1.0 indicates that survival is better in the PC arm than in the GC arm. Alternatively, a HR that is greater than 1.0 indicates survival is better in the GC arm than in the PC arm.
Pemetrexed for Injection plus Cisplatin
(N=862)
Gemcitabine plus Cisplatin
(N=863)
Median overall survival (95% CI) 10.3 mos (9.8-11.2) 10.3 mos (9.6-10.9)
 Adjusted hazard ratio (HR)a,b (95% CI) 0.94 (0.84-1.05)
Median progression-free survival (95% CI) 4.8 mos (4.6-5.3) 5.1 mos (4.6-5.5)
 Adjusted hazard ratio (HR)a,b (95% CI) 1.04 (0.94-1.15)
Overall response rate (95% CI) 27.1% (24.2-30.1) 24.7% (21.8-27.6)
Table 12: First-Line Therapy: Overall Survival in NSCLC Histologic Subgroups
a A HR that is less than 1.0 indicates that survival is better in the PC arm than in the GC arm. Alternatively, a HR that is greater than 1.0 indicates survival is better in the GC arm than in the PC arm.
b Unadjusted for multiple comparisons.
c HRs adjusted for ECOG PS, gender, disease stage, and basis for pathological diagnosis (histopathological/cytopathological).
d Includes adenocarcinoma, large cell, and other histologies except those with squamous cell type.
e The subgroup of "other" represents patients with a primary diagnosis of NSCLC whose disease did not clearly qualify as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.
Histology Subgroup Median Overall Survival in Months
(95% CI)
Unadjusted
Hazard Ratio (HR)a,b (95% CI)
Adjusted Hazard Ratio (HR)a,b,c
(95% CI)
Pemetrexed for Injection plus Cisplatin Gemcitabine plus Cisplatin
Nonsquamous NSCLCd
(N=1252)
11.0
(10.1-12.5)
N=618 10.1
(9.3-10.9)
N=634 0.84
(0.74-0.96)
0.84
(0.74-0.96)
  Adenocarcinoma
   (N=847)
12.6
(10.7-13.6)
N=436 10.9
(10.2-11.9)
N=411 0.84
(0.71-0.98)
0.84
(0.71-0.99)
  Large Cell
   (N=153)
10.4
(8.6-14.1)
N=76 6.7
(5.5-9.0)
N=77 0.68
(0.48-0.97)
0.67
(0.48-0.96)
  Othere
   (N=252)
8.6
(6.8-10.2)
N=106 9.2
(8.1-10.6)
N=146 1.12
(0.84-1.49)
1.08
(0.81-1.45)
 Squamous Cell
   (N=473)
9.4
(8.4-10.2)
N=244 10.8
(9.5-12.1)
N=229 1.22
(0.99-1.50)
1.23
(1.00-1.51)

Pemetrexed for Injection Maintenance Following Non-Pemetrexed for Injection Containing Platinum-Based, Induction Therapy

A multi-center, randomized, double-blind, placebo-controlled study was conducted in 663 patients with Stage IIIb/IV NSCLC who did not progress after four cycles of platinum-based chemotherapy. Patients who did not progress were randomized 2:1 to receive Pemetrexed for Injection or placebo immediately following platinum-based chemotherapy. Of the randomized patients, 47.2% versus 52.7% achieved a complete or partial response to induction therapy and 51.9% versus 47.3% had stable disease after induction therapy in the Pemetrexed for Injection and placebo arms, respectively. Pemetrexed for Injection was administered intravenously over 10 minutes at a dose of 500 mg/m on Day 1 of each 21-day cycle, until disease progression. Patients in both study arms received folic acid, vitamin B, and dexamethasone [see Dosage and Administration (2.3)].

The study was designed to demonstrate superior progression-free survival and overall survival of Pemetrexed for Injection over placebo. Progression-free survival (PFS) was assessed by independent review. Patient characteristics of the intent to treat (ITT) population are shown in Table 13. The demographics and baseline disease characteristics were well balanced between study arms.

Patients received a median of 5 cycles of Pemetrexed for Injection and 3.5 cycles of placebo. Patients randomized to Pemetrexed for Injection received a relative dose intensity of 95.7%. A total of 213 patients (48.3%) completed ≥6 cycles and a total of 98 patients (22.6%) completed ≥10 cycles of treatment with Pemetrexed for Injection.

In the overall study population, Pemetrexed for Injection was statistically superior to placebo in terms of overall survival (OS) (median 13.4 months versus 10.6 months, HR=0.79 (95% CI: 0.65-0.95), p-value=0.012) and PFS (median 4.0 months versus 2.0 months, HR=0.60 (95% CI: 0.49-0.73), p-value<0.00001). A difference in treatment outcomes was observed according to histologic classification. For the population of patients with nonsquamous NSCLC, Pemetrexed for Injection was superior to placebo for OS (median 15.5 months versus 10.3 months, HR=0.70 (95% CI: 0.56-0.88)) and PFS (median 4.4 months versus 1.8 months, HR=0.47 (95% CI: 0.37-0.60)). For the population of patients with squamous NSCLC, Pemetrexed for Injection did not improve OS compared to placebo (median 9.9 months versus 10.8 months, HR=1.07 (95% CI: 0.77-1.50)) or PFS (median 2.4 months versus 2.5 months, HR=1.03 (95% CI: 0.71-1.49)). This difference in treatment effect for Pemetrexed for Injection based on histology demonstrating lack of benefit in squamous cell histology was also observed in the first-line and second-line studies. [see Clinical Studies (14.1, 14.3)]

Efficacy results for the overall patient population are presented in Table 14 and Figure 3, and efficacy results by pre-specified histologic subgroups are presented in Table 15 and Figure 4, below.

Figure 3: Kaplan-Meier Curve for Overall Survival Pemetrexed for Injection (P) versus Placebo (P) in NSCLC – ITT Population.

Figure 4: Kaplan-Meier Curves for Overall Survival Pemetrexed for Injection versus Placebo in NSCLC – Nonsquamous NSCLC and Squamous Cell NSCLC.

Table 13: Maintenance Therapy Following Platinum-Based Induction Therapy: Summary of Patient Characteristics in Study of NSCLC
a Stage at Entry was not reported for all randomized patients. Percentages are representative of N=440 for the Pemetrexed for Injection arm and N=222 for the placebo arm.
b Includes patients with adenocarcinoma, large cell, and other histologic diagnoses.
c The subgroup of “Other” represents patients with a primary diagnosis of NSCLC whose disease did not clearly qualify as adenocarcinoma, large cell carcinoma, or squamous cell carcinoma.
d Eastern Cooperative Oncology Group Performance Status (ECOG PS) was not reported for all randomized patients. Percentages are representative of N=439 for the Pemetrexed for Injection arm, and N=222 for the placebo arm.
e Smoking history was not reported for all randomized patients. Percentages are representative of N=437 for the Pemetrexed for Injection arm and N=221 for the placebo arm.
Patient characteristic Pemetrexed for Injection
(N=441)
Placebo
(N=222)
Age (yrs)
  Median (range) 60.6 (25.6-82.6) 60.4 (35.4-78.5)
Gender
  Male/Female 73.0%/27.0% 72.5%/27.5%
Ethnic Origin
  Caucasian 279 (63.3%) 149 (67.1%)
  East Asian 104 (23.6%) 50 (22.5%)
  Other 58 (13.2%) 23 (10.4%)
Stage at Entry a
  IIIb/IV 18.0%/82.0% 21.2%/78.8%
Histology (%)
  Nonsquamous NSCLCb 325 (73.7%) 156 (70.3%)
    Adenocarcinoma 222 (50.3%) 106 (47.7%)
    Large cell 10 (2.3%) 10 (4.5%)
    Otherc 93 (21.1%) 40 (18.0%)
  Squamous 116 (26.3%) 66 (29.7%)
ECOG PSd
   0/1 40.1%/59.9% 38.3%/61.7%
Smoking Historye
  Ever/never smoker 74.1%/25.9% 71.5%/28.5%
Time from start of induction therapy to study randomization (months)
  Median (range) 3.25 (1.6-4.8) 3.29 (2.7-5.1)
Table 14: Maintenance Therapy Following Platinum-Based Induction Therapy: Efficacy of Pemetrexed for Injection versus Placebo in NSCLC – ITT Population
a PFS and OS were calculated from time of randomization, after completion of 4 cycles of induction platinum-based chemotherapy.
b Values for PFS given based on independent review (Pemetrexed for Injection N=387, Placebo N=194).
c Unadjusted hazard ratios are provided. A HR <1.0 indicates that the result is better in the Pemetrexed for Injection arm than in the placebo arm.
Efficacy Parametera,b Pemetrexed for Injection
(N=441)
Placebo
(N=222)
 Median overall survivalc (95% CI) 13.4 mos (11.9-15.9) 10.6 mos (8.7-12.0)
  Hazard ratio (HR)c (95% CI) 0.79 (0.65-0.95)
  p-value p=0.012
 Median progression-free survival (95% CI) 4.0 mos (3.1-4.4) 2.0 mos (1.5-2.8)
  Hazard ratio (HR)c (95% CI) 0.60 (0.49-0.73)
  p-value p<0.00001
Table 15: Maintenance Therapy Following Platinum-Based Induction Therapy: Efficacy in NSCLC by Histologic Subgroupsa
a PFS and OS were calculated from time of randomization, after completion of 4 cycles of induction platinum-based chemotherapy. All results unadjusted for multiple comparisons.
b Values for PFS are given based on independent review (Pemetrexed for Injection N=387, Placebo N=194).
c Unadjusted hazard ratios are provided. A HR <1.0 indicates that the result is better in the Pemetrexed for Injection arm than in the placebo arm. A HR >1.0 indicates that the result is better in the placebo arm than in the Pemetrexed for Injection arm.
d Includes patients with adenocarcinoma, large cell carcinoma, and other histology.
e The subgroup of “Other” represents patients with a primary diagnosis of NSCLC whose disease did not clearly qualify as adenocarcinoma, large cell carcinoma, or squamous cell carcinoma.
Overall Survival Progression-Free Survivalb
Pemetrexed for Injection Placebo Pemetrexed for Injection Placebo
Median (months) Median (months) Median (months) Median (months)
HRc (95% CI) HRc (95% CI)
Nonsquamous NSCLCd 15.5 10.3 4.4 1.8
N=481 0.70 (0.56-0.88) 0.47 (0.37-0.60)
  Adenocarcinoma 16.8 11.5 4.6 2.7
  N=328 0.73 (0.56-0.96) 0.51 (0.38-0.68)
  Large cell carcinoma 8.4 7.9 4.5 1.5
  N=20 0.98 (0.36-2.65) 0.40 (0.12-1.29)
  Othere 11.3 7.7 4.1 1.6
  N=133 0.61 (0.40-0.94) 0.44 (0.28-0.68)
Squamous cell 9.9 10.8 2.4 2.5
N=182 1.07 (0.77-1.50) 1.03 (0.71-1.49)

Continuation of Pemetrexed for Injection as Maintenance Following Pemetrexed for Injection Plus Platinum Induction Therapy

A multi-center, randomized, double-blind, placebo-controlled study was conducted to evaluate continuation of Pemetrexed for Injection in patients with Stage IIIb/IV nonsquamous NSCLC. Patients completing induction treatment of four cycles of Pemetrexed for Injection plus cisplatin with stable disease or better and PS 0/1 were randomized (2:1) to maintenance treatment with Pemetrexed for Injection or placebo. Randomization was stratified by response to induction (complete response (CR)/partial response (PR) versus stable disease (SD)), disease stage (IIIb versus IV), and ECOG performance status (0 versus 1). Pemetrexed for Injection was administered intravenously over 10 minutes at a dose of 500 mg/m on Day 1 of each 21-day cycle and continued until disease progression. Patients in both study arms received folic acid, vitamin B, and dexamethasone [see Dosage and Administration (2.3)]. The main efficacy outcome was investigator-assessed progression-free survival.

A total of 539 patients were randomized; all completed four cycles of Pemetrexed for Injection and cisplatin induction prior to randomization. Of the randomized patients, 44% versus 42% achieved a complete or partial response to induction therapy and 53% versus 53% had stable disease after induction treatment in the Pemetrexed for Injection or the placebo arms respectively.

Patient demographics of the intent to treat (ITT) population are shown in Table 16.

Patients received a median of four cycles of Pemetrexed for Injection maintenance or placebo. The percentages of patients that received post-study treatment were similar (64% in the Pemetrexed for Injection arm and 72% in the placebo arm).

The trial showed a statistically significant improvement in progression-free survival and in overall survival for patients randomized to Pemetrexed for Injection maintenance. Efficacy results are presented in Table 17 and Figure 5.

Figure 5: Kaplan-Meier Curves for Overall Survival Pemetrexed for Injection versus Placebo in Nonsquamous NSCLC Following Pemetrexed for Injection Plus Cisplatin Induction Therapy.

Table 16: Pemetrexed for Injection as Maintenance Therapy Following Pemetrexed for Injection Plus Cisplatin Induction Therapy: Summary of Patient Characteristics in Study of Nonsquamous NSCLC
a Histological or cytological diagnosis of NSCLC defined as other than predominantly squamous cell histology (squamous cell and/or mixed small cell, non-small cell histology were not permitted on this study).
b The subcategory of “Other” represents patients with a primary diagnosis of NSCLC whose disease did not clearly qualify as adenocarcinoma or large-cell carcinoma.
c Smoking history was not reported for all randomized patients.
Patient characteristic Pemetrexed for Injection
(N=359)
Placebo
(N=180)
Age (yrs)
     Median 61.0 62.4
     Range 31.9-78.7 34.9-83.3
Gender (%)
     Male 201 (56%) 112 (62%)
     Female 158 (44%) 68 (38%)
Ethnic Origin (%)
     Caucasian 339 (94%) 171 (95%)
     Asian 16 (4.5%) 8 (4.4%)
     African 4 (1.1%) 1 (0.6%)
Stage at Entry
     IIIb 31 (9%) 18 (10%)
     IV 328 (91%) 162 (90%)
Histology (%)
     Nonsquamous NSCLCa
               Adenocarcinoma 310 (86%) 161 (89%)
               Large cell 24 (7%) 12 (7%)
               Otherb 25 (7%) 7 (3.9%)
ECOG PS (%)
     0 113 (32%) 60 (33%)
     1 245 (68%) 118 (66%)
Smoking History c
     Ever 274 (76%) 144 (80%)
     Never smoker 83 (23%) 34 (19%)
Table 17: Pemetrexed for Injection Maintenance Therapy Following Pemetrexed for Injection Plus Cisplatin Induction Therapy: Efficacy of Pemetrexed for Injection versus Placebo in Nonsquamous NSCLC
a PFS and OS were calculated from time of randomization, after completion of 4 cycles of Pemetrexed for Injection plus cisplatin induction therapy.
b Values for PFS given based on investigator assessment.
c A hazard ratio of less than 1 indicates that the maintenance treatment with pemetrexed is associated with lower risk of progression or death compared to treatment with placebo.
Efficacy Parametera,b Pemetrexed for Injection
(N=359)
Placebo
(N=180)
 Median overall survivalc (95% CI) 13.9 mos (12.8-16.0) 11.0 mos (10.0-12.5)
               Hazard ratio (HR)c (95% CI) 0.78 (0.64-0.96)
               p-value p=0.02
 Median progression-free survival (95% CI) 4.1 mos (3.2-4.6) 2.8 mos (2.6-3.1)
               Hazard ratio (HR)c (95% CI) 0.62 (0.49-0.79)
               p-value p<0.0001

A multi-center, randomized, open label study was conducted in patients with Stage III or IV NSCLC after prior chemotherapy to compare the overall survival following treatment with Pemetrexed for Injection versus docetaxel. Pemetrexed for Injection was administered intravenously over 10 minutes at a dose of 500 mg/m and docetaxel was administered at 75 mg/m as a 1-hour intravenous infusion. Both drugs were given on Day 1 of each 21-day cycle. All patients treated with Pemetrexed for Injection received vitamin supplementation with folic acid and vitamin B. The study was intended to show either an overall survival superiority or non-inferiority of Pemetrexed for Injection to docetaxel. Patient demographics of the intent to treat (ITT) population are shown in Table 18.

The primary endpoint in this study was overall survival. The median survival time was 8.3 months in the Pemetrexed for Injection treatment arm and 7.9 months in the docetaxel arm, with a hazard ratio of 0.99 (see Table 19). The study did not show an overall survival superiority of Pemetrexed for Injection.

A retrospective analysis of the impact of NSCLC histology on overall survival was examined. Clinically relevant differences in survival according to histology were observed and are shown in Table 20. This difference in treatment effect for Pemetrexed for Injection based on histology demonstrating a lack of efficacy in squamous cell histology was also observed in the first-line combination study and in the maintenance study [see Clinical Studies (14.1, 14.2)].

Table 18: Second-Line Therapy: Summary of Patient Characteristics in NSCLC Study
a Performance status was not reported for all randomized patients. Percentages are representative of N=264 for the Pemetrexed for Injection arm and N=274 for the docetaxel arm.
 Patient characteristic Pemetrexed for Injection
(N=283)
Docetaxel
(N=288)
 Age (yrs)
   Median (range) 59 (22-81) 57 (28-87)
 Gender (%)
   Male/Female 68.6/31.4 75.3/24.7
 Stage at Entry (%)
   III/IV 25.1/74.9 25.3/74.7
 Diagnosis/Histology (%)
   Adenocarcinoma 154 (54.4) 142 (49.3)
   Squamous 78 (27.6) 94 (32.6)
   Bronchoalveolar 4 (1.4) 1 (0.3)
   Other 47 (16.6) 51 (17.7)
 Performance Status (%)a
   0-1 234 (88.6) 240 (87.6)
   2 30 (11.4) 34 (12.4)
Table 19: Efficacy of Pemetrexed for Injection versus Docetaxel in Non-Small Cell Lung Cancer – ITT Population
Pemetrexed for Injection
(N=283)
Docetaxel
(N=288)
 Median overall survival (95% CI) 8.3 mos (7.0-9.4) 7.9 mos (6.3-9.2)
  Hazard ratio (HR) (95% CI) 0.99 (0.82-1.20)
 Median progression-free survival (95% CI) 2.9 mos (2.4-3.1) 2.9 mos (2.7-3.4)
  Hazard ratio (HR) (95% CI) 0.97 (0.82-1.16)
 Overall response rate (95% CI) 8.5% (5.2-11.7) 8.3% (5.1-11.5)
Table 20: Second-Line Therapy: Overall Survival of Pemetrexed for Injection versus Docetaxel in NSCLC by Histologic Subgroups
a A HR that is less than 1.0 indicates that survival is better in the Pemetrexed for Injection arm than in the docetaxel arm. Alternatively, a HR that is greater than 1.0 indicates survival is better in the docetaxel arm than in the Pemetrexed for Injection arm.
b Unadjusted for multiple comparisons.
c HRs adjusted for ECOG PS, time since prior chemotherapy, disease stage, and gender.
d Includes adenocarcinoma, large cell, and other histologies except those with squamous cell type.
e The subgroup of “other” represents patients with a primary diagnosis of NSCLC whose disease did not clearly qualify as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.
Histology Subgroup Median Overall Survival in Months
(95% CI)
Unadjusted Hazard Ratio (HR)a,b
(95% CI)
Adjusted Hazard Ratio (HR)a,b,c
(95% CI)
Pemetrexed for Injection Docetaxel
Nonsquamous NSCLCd
(N=399)
9.3
(7.8-9.7)
N=205 8.0
(6.3-9.3)
N=194 0.89
(0.71-1.13)
0.78
(0.61-1.00)
   Adenocarcinoma
    (N=301)
9.0
(7.6-9.6)
N=158 9.2
(7.5-11.3)
N=143 1.09
(0.83-1.44)
0.92
(0.69-1.22)
   Large Cell
   (N=47)
12.8
(5.8-14.0)
N=18 4.5
(2.3-9.1)
N=29 0.38
(0.18-0.78)
0.27
(0.11-0.63)
   Othere
   (N=51)
9.4
(6.0-10.1)
N=29 7.9
(4.0-8.9)
N=22 0.62
(0.32-1.23)
0.57
(0.27-1.20)
Squamous Cell
(N=172)
6.2
(4.9-8.0)
N=78 7.4
(5.6-9.5)
N=94 1.32
(0.93-1.86)
1.56
(1.08-2.26)

A multi-center, randomized, single-blind study in 448 chemonaive patients with malignant pleural mesothelioma (MPM) compared survival in patients treated with Pemetrexed for Injection in combination with cisplatin to survival in patients receiving cisplatin alone. Pemetrexed for Injection was administered intravenously over 10 minutes at a dose of 500 mg/m and cisplatin was administered intravenously over 2 hours at a dose of 75 mg/m beginning approximately 30 minutes after the end of administration of Pemetrexed for Injection. Both drugs were given on Day 1 of each 21-day cycle. After 117 patients were treated, white cell and GI toxicity led to a change in protocol whereby all patients were given folic acid and vitamin B supplementation.

The primary analysis of this study was performed on the population of all patients randomly assigned to treatment who received study drug (randomized and treated). An analysis was also performed on patients who received folic acid and vitamin B supplementation during the entire course of study therapy (fully supplemented), as supplementation is recommended [see Dosage and Administration (2.3)]. Results in all patients and those fully supplemented were similar. Patient demographics are shown in Table 21.

Table 22 and Figure 6 summarize the survival results for all randomized and treated patients regardless of vitamin supplementation status and those patients receiving vitamin supplementation from the time of enrollment in the trial.

Similar results were seen in the analysis of patients (N=303) with confirmed histologic diagnosis of malignant pleural mesothelioma. There were too few non-white patients to assess possible ethnic differences. The effect in women (median survival 15.7 months with the combination versus 7.5 months on cisplatin alone), however, was larger than the effect in males (median survival 11 versus 9.4 respectively). As with any exploratory analysis, it is not clear whether this difference is real or is a chance finding.

Figure 6: Kaplan-Meier Estimates of Survival Time for Pemetrexed for Injection plus Cisplatin and Cisplatin Alone in all Randomized and Treated Patients.

Objective tumor response for malignant pleural mesothelioma is difficult to measure and response criteria are not universally agreed upon. However, based upon prospectively defined criteria, the objective tumor response rate for Pemetrexed for Injection plus cisplatin was greater than the objective tumor response rate for cisplatin alone. There was also improvement in lung function (forced vital capacity) in the Pemetrexed for Injection plus cisplatin arm compared to the control arm.

Patients who received full supplementation with folic acid and vitamin B during study therapy received a median of 6 and 4 cycles in the Pemetrexed for Injection/cisplatin (N=168) and cisplatin (N=163) arms, respectively. Patients who never received folic acid and vitamin B during study therapy received a median of 2 cycles in both treatment arms (N=32 and N=38 for the Pemetrexed for Injection/cisplatin and cisplatin arm, respectively). Patients receiving Pemetrexed for Injection in the fully supplemented group received a relative dose intensity of 93% of the protocol specified Pemetrexed for Injection dose intensity; patients treated with cisplatin in the same group received 94% of the projected dose intensity. Patients treated with cisplatin alone had a dose intensity of 96%.

Table 21: Summary of Patient Characteristics in MPM Study
a Only 67% of the patients had the histologic diagnosis of malignant mesothelioma confirmed by independent review.
b Karnofsky Performance Scale.
Randomized and Treated Patients Fully Supplemented Patients
 Patient characteristic Pemetrexed for Injection/cis
(N=226)
Cisplatin
(N=222)
Pemetrexed for Injection/cis
(N=168)
Cisplatin
(N=163)
 Age (yrs)
   Median (range) 61 (29-85) 60 (19-84) 60 (29-85) 60 (19-82)
 Gender (%)
   Male 184 (81.4) 181 (81.5) 136 (81.0) 134 (82.2)
   Female 42 (18.6) 41 (18.5) 32 (19.0) 29 (17.8)
 Origin (%)
   Caucasian 204 (90.3) 206 (92.8) 150 (89.3) 153 (93.9)
   Hispanic 11 (4.9) 12 (5.4) 10 (6.0) 7 (4.3)
   Asian 10 (4.4) 4 (1.9) 7 (4.2) 3 (1.8)
   African descent 1 (0.4) 0 1 (0.6) 0
 Stage at Entry (%)
   I 16 (7.1) 14 (6.3) 15 (8.9) 12 (7.4)
   II 35 (15.6) 33 (15.0) 27 (16.2) 27 (16.8)
   III 73 (32.4) 68 (30.6) 51 (30.5) 49 (30.4)
   IV 101 (44.9) 105 (47.2) 74 (44.3) 73 (45.3)
   Unspecified 1 (0.4) 2 (0.9) 1 (0.6) 2 (1.2)
 Diagnosis/Histologya (%)
   Epithelial 154 (68.1) 152 (68.5) 117 (69.6) 113 (69.3)
   Mixed 37 (16.4) 36 (16.2) 25 (14.9) 25 (15.3)
   Sarcomatoid 18 (8.0) 25 (11.3) 14 (8.3) 17 (10.4)
   Other 17 (7.5) 9 (4.1) 12 (7.1) 8 (4.9)
 Baseline KPSb (%)
   70-80 109 (48.2) 97 (43.7) 83 (49.4) 69 (42.3)
   90-100 117 (51.8) 125 (56.3) 85 (50.6) 94 (57.7)
Table 22: Efficacy of Pemetrexed for Injection plus Cisplatin versus Cisplatin in Malignant Pleural Mesothelioma
a p-value refers to comparison between arms.
Randomized and Treated Patients Fully Supplemented Patients
Efficacy Parameter Pemetrexed for Injection/cis
(N=226)
Cisplatin
(N=222)
Pemetrexed for Injection/cis
(N=168)
Cisplatin
(N=163)
   Median overall survival 12.1 mos 9.3 mos 13.3 mos 10.0 mos
   (95% CI) (10.0-14.4) (7.8-10.7) (11.4-14.9) (8.4-11.9)
   Hazard ratio 0.77 0.75
   Log rank p-valuea 0.020 0.051

Pemetrexed for Injection, is available in sterile single-use vials containing 100 mg pemetrexed.

   NDC 67184-0503-1: single-use vial with blue cap individually packaged in a carton.

Pemetrexed for Injection, is available in sterile single-use vials containing 500 mg pemetrexed.

   NDC 67184-0504-1: single-use vial with blue cap individually packaged in a carton.

Pemetrexed for Injection should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Chemical and physical stability of reconstituted and infusion solutions of Pemetrexed for Injection were demonstrated for up to 24 hours following initial reconstitution, when stored refrigerated, 2-8°C (36-46°F). When prepared as directed, reconstituted and infusion solutions of Pemetrexed for Injection contain no antimicrobial preservatives. Discard unused portion [see Dosage and Administration (2.5)].

Pemetrexed for Injection is not light sensitive.

See FDA-Approved Patient Labeling (PPI)

Instruct patients to read the patient package insert before initiating Pemetrexed for Injection.

Qilu Pharma, INC. Malvern, PA, USA 19355

Manufactured by: Qilu Pharmaceutical (Hainan) Co.,Ltd.

Haikou, Hainan 570314, China

PATIENT INFORMATIONPemetrexed for Injection

Read the Patient Information that comes with Pemetrexed for Injection before you start treatment and each time you get treated with Pemetrexed for Injection. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment. Talk to your doctor if you have any questions about Pemetrexed for Injection.

What is Pemetrexed for Injection?

Pemetrexed for Injection is a treatment for:

To lower your chances of side effects of Pemetrexed for Injection, you must also take folic acid and vitamin B prior to and during your treatment with Pemetrexed for Injection. Your doctor will prescribe a medicine called a “corticosteroid” to take for 3 days during your treatment with Pemetrexed for Injection.

In children, Pemetrexed for Injection has not been shown to be effective. No important differences in side effects were seen in children compared to adults (see “What are the possible side effects of Pemetrexed for Injection?”).

What should I tell my doctor before taking Pemetrexed for Injection?

Tell your doctor about all of your medical conditions, including if you:

How is Pemetrexed for Injection given?

What should I avoid while taking Pemetrexed for Injection?

What are the possible side effects of Pemetrexed for Injection?

Most patients taking Pemetrexed for Injection will have side effects. Sometimes it is not always possible to tell whether Pemetrexed for Injection, another medicine, or the cancer itself is causing these side effects. Call your doctor right away if you have a fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection which may be severe and could lead to death.

The most common side effects of Pemetrexed for Injection when given alone or in combination with cisplatin are:

Talk with your doctor, nurse, or pharmacist about any side effect that bothers you or that doesn't go away.

These are not all the side effects of Pemetrexed for Injection. For more information, ask your doctor, nurse, or pharmacist.

General information about Pemetrexed for Injection

Medicines are sometimes prescribed for conditions other than those listed in patient information leaflets. Pemetrexed for Injection was prescribed for your medical condition.

This leaflet summarizes the most important information about Pemetrexed for Injection. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Pemetrexed for Injection that is written for health professionals.

Revised February 2016

Qilu Pharma, INC. Malvern, PA, USA 19355

Manufactured by: Qilu Pharmaceutical (Hainan) Co.,Ltd.

Haikou, Hainan 570314, China

PACKAGE CARTON – Pemetrexed for Injection 100 mg single-use vial

NDC 67184-0503-1

Single-Use Vial

Pemetrexed for Injection

100 mg/vial

For intravenous Use only.

Rx only

PACKAGE CARTON – Pemetrexed for Injection 500 mg single-use vial

Single-Use Vial

NDC 67184-0504-1

Pemetrexed for Injection

500 mg/vial

For intravenous use only.

Rx only

Manufacturer

Qilu Pharmaceutical Co., Ltd.

Active Ingredients

Source

Drugs and Medications [5 Associated Drugs and Medications listed on BioPortfolio]

Alimta [eli lilly and company]

These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA.ALIMTA (pemetrexed for injection), for Intravenous UseIniti...

Indomethacin [preferred pharmaceuticals, inc.]

Indomethacin PAS These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES. Indomethaci...

Gilotrif [boehringer ingelheim pharmaceuticals, inc.]

These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. GILOTRIF (afatinib) tablets, for oral useInitial U.S. ...

Portrazza [eli lilly and company]

These highlights do not include all the information needed to use PORTRAZZA safely and effectively. See full prescribing information for PORTRAZZA. PORTRAZZA (necitumumab) injection, for intravenous u...

Xalkori [pfizer laboratories div pfizer inc]

These highlights do not include all the information needed to use XALKORI safely and effectively. See full prescribing information for XALKORI. XALKORI (crizotinib) capsules, for oral use Initial U.S....

Clinical Trials [423 Associated Clinical Trials listed on BioPortfolio]

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

The purposes of this study are to determine: - the safety of pemetrexed and any side effects that might be associated with it - how much pemetrexed should be given to patients. ...

A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned

The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung c...

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

The aim of this study is to compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastat...

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

The purposes of this study are to determine: 1. The safety of pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. ...

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin ...

PubMed Articles [18 Associated PubMed Articles listed on BioPortfolio]

Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed/carboplatin combination chemotherapy.

Pemetrexed/carboplatin combination chemotherapy has shown efficacy as a first-line treatment for advanced non-small-cell lung cancer. However, severe haematotoxicity is often observed during this comb...

Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.

Vitamin B12 and folic acid (FA) supplementation (B12-FAS) reduces hematologic toxicity with pemetrexed-based chemotherapy (PEM). However, the basis for recommending 1 week of B12-FAS before PEM initi...

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer.

The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose of pemetrexed with concurrent thoracic radiation therapy for elderly patients with previously untreated loca...

A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.

Thymoma and thymic carcinoma are neoplastic diseases with reported chemosensitivity to a broad range of agents. However, due to the rarity of these diseases, few prospective trials have been conducted...

24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for advanced nonsquamous NSCLC. At the p...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record